Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
boston blog main
boston top stories
editas medicine
gene editing
life sciences
national blog main
allergan
clinical trials
crispr
cynthia collins
san francisco blog main
abbvie
agios therapeutics
alzheimer's disease
base editing
branden moriarty
broad institute
cas13
crispr therapeutics
crispr-cas9
david liu
deals
dna
drugs
editor
editr
enzyme
feng zhang
harvard university
intellia therapeutics
john evans
katrine bosley
keith joung
leber congenital amaurosis
leber congenital amaurosis type 10
massachusetts general hospital
michelle robertson
national top stories
What
editas
3
×
editing
gene
3
×
crispr
experimental
medicine
abbvie
allergan
alliance
beam
biotech
blessing
bosley
cas
ceo
check
clinical
cusp
depart
editor
exits
founders
genetic
gotten
harvard
humans
jump
katrine
mass
medicines
million
pact
partner
partnership
precise
pruning
regulatory
research
returning
rights
Language
unset
Current search:
gene
×
editas
×
biotech
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M